N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05
Phase 3 N=373 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale — -3.10; -3.49; -2.80 units on a scale
Phase 4 N=28 Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
Pruritis
Primary: Investigator Global Assessment — 2.63; 2.32 units on a scale
Phase 4 N=50 A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
Pruritis
Primary: Severity of Pruritis — 10.88; 9.76; 6.64; 5.12 units on a scale
Phase 3 N=175 Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score During Week 8 — -3.8; -2.8; -3.2; -1.9 score on a scale — p=<0.001
Phase 3 N=258 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Primary: Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 — 38.5; 47.7; 32.4…
N/A N=60 Evaluation of the Efficacy of Laser Acupuncture on Uremic Pruritus
Uremia
Primary: Title: Evaluation of the Efficacy of Laser Acupuncture on Ureimc Pruritus — 18.13; 17.47; 10.20; 17.10 points — p=<0.05
Phase 2 N=247 A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Uremic Pruritus
Primary: Change From Baseline in the Mean NRS Score at Week 8 of the Treatment Period — -2.97; -3.65; -3.64; -2.86 points — p=0.770
Phase 2 N=269 A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Chronic Kidney Diseases · Pruritus
Primary: Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 — -3.99; -3.84; -4.42; -3.32 score on…
Phase 3 N=178 A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Uremic Pruritus
Primary: Change From Baseline in the Mean NRS Score at Week 4 — -2.06; -1.09 points — p=<0.001
Phase 2 N=111 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Chronic Kidney Disease-associated Pruritus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -3.70; -3.87 score on a scale
Phase 3 N=222 CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Number of Participants With AEs. — 143 Participants
Phase 3 N=167 Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs) — 133 Participants
Phase 1 N=40 Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
Pruritus · Cholestasis · Kidney Failure
Primary: Incidence of Adverse Events — 5; 5; 5; 3 participants
Phase 2 N=9 Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Pruritus
Primary: Change in Peak Pruritus Numerical Rating Score (PRNS) — -3.1 score on a scale
Phase 3 N=236 Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis
Uremic Xerosis
Primary: Treatment Response of Xerosis — 71; 48 participants
Phase 2 N=20 Topical Aprepitant in Prurigo Patients
Pruritus
Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58
Phase 2 N=233 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Pruritus
Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861
Phase 3 N=378 A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Uremic Pruritus
Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…
Phase 3 N=288 Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Number of Participants With AEs — 240 Participants
Phase 3 N=353 PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Prurigo Nodularis
Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…
Phase 3 N=471 CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…
Phase 3 N=295 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158
Phase 3 N=285 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 — 26.45; 20.31 Percentage of subjects — p=0.229
Phase 3 N=62 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Prurigo Nodularis · Nodularis Prurigo · Prurigo
Primary: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale — 27.3; 44.4; 36.4 percentage of subjects
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Phase 2 N=10 A Study Examining the Medication Apremilast as Treatment for Chronic Itch
Itch
Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale
Phase 2 N=484 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Pruritus · Atopic Dermatitis
Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale